Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 674.95

+3.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	6/1/2020 2:16:21 PM
	Read Replies (1) of 3557

REGN and NTLA Doubt very much that CRISPR/Cas9-based therapeutic is a way to go (REGN continue to stick to biologic),.... finance.yahoo.com TARRYTOWN, N.Y. and CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilitiesRegeneron gains rights to develop products for additional in vivo targets and new rights for ex vivo product developmentIntellia receives $100 million through upfront cash and equity investment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next